<DOC>
	<DOCNO>NCT00003555</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Chemoprotective drug , amifostine , may protect normal cell side effect chemotherapy . PURPOSE : Phase I trial study effectiveness paclitaxel plus chemoprotection amifostine treat patient recurrent refractory solid tumor .</brief_summary>
	<brief_title>Paclitaxel Plus Chemoprotection With Amifostine Treating Patients With Recurrent Refractory Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose weekly paclitaxel follow amifostine patient recurrent refractory solid tumor . II . Assess tumor response rate survival patient . OUTLINE : This dose escalation study paclitaxel . Patients receive amifostine IV 5 minute less day 0 , follow paclitaxel IV 1 hour week 6 week follow 2 week rest . Patients complete partial response may receive additional course therapy . Cohorts 3-5 patient receive increase dos paclitaxel . The maximum tolerate dose define dose level prior cohort 1 3-5 patient experience dose limit toxicity . PROJECTED ACCRUAL : Approximately 20 patient accrue study .</detailed_description>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Amifostine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven recurrent refractory solid tumor Evaluable disease PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Greater 4 month Hematopoietic : Neutrophil count least 2,000/mm3 Platelet count least 100,000/mm3 Hemoglobin least 8 g/dL Hepatic : Bilirubin le 1.5 g/dL Alkaline phosphatase less 3 time upper limit normal ( ULN ) AST le 3 time ULN Renal : Calcium great 8 mg/dL Creatinine clearance great 60 mL/min Cardiovascular : No active congestive heart failure Other : Not pregnant nursing Fertile patient must use effective contraception No grade 2 neuropathy No intolerability hydration PRIOR CONCURRENT THERAPY : Biologic therapy : Prior biologic therapy allow Chemotherapy : No 3 prior fail chemotherapy regimen Prior paclitaxel radiosensitizer allow No prior weekly paclitaxel infusion failure Prior platinum paclitaxel therapy allow Endocrine therapy : Prior endocrine therapy allow Radiotherapy : Prior radiotherapy allow Surgery : Prior surgery allow Other : No concurrent dilantin therapy No antihypertensive/diuretics within 24 hour prior chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2006</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>